# Inclisiran, Reasons for a Novel Agent in a Crowded Therapeutic Field

Review · Di Giacomo-Barbagallo F, Andreychuk N, Scicali R, Gonzalez-Lleó A, Piro S, Masana L, Ibarretxe D

- Archive id: doi:10.1007/s11883-024-01271-x
- Published: 2025-01-09
- Venue: Current atherosclerosis reports
- DOI: https://doi.org/10.1007/s11883-024-01271-x
- PMID: 39786678
- PMCID: PMC11717820
- Citations: 26
- Source URL: https://doi.org/10.1007/s11883-024-01271-x
- PDF: https://europepmc.org/articles/PMC11717820/pdf
- Provenance: europepmc

## Abstract

Purpose of the review A significant number of patients fail to achieve target LDL cholesterol (LDL-C) levels. This review aims to explore why inclisiran, a novel class of LLT, should be considered a valuable addition to the current treatment options. Recent findings Inclisiran is a small interfering RNA (siRNA) that targets PCSK9 synthesis specifically in the hepatocytes. The drug remains in circulation for less than 48 h, but its effect lasts for over six months. Two subcutaneous injections per year consistently lowers LDL-C by approximately 55% with a favorable safety profile. In combination with other LLTs, it can achieve LDL-C reductions of over 80%, supporting its role in high-intensity LLT strategies. Inclisiran represents a novel class of LLT. Administered biannually, reduces baseline LDL-C levels by half. Additionally, it has a strong safety profile. Due to its pharmacokinetic properties, is likely to improve adherence to LLT and persistently maintain low LDL-C levels.

_Abstract reproduced under CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)._

Topics: [Cardiovascular Therapeutics](https://space-kitty.com/topics/cardiovascular-innovation)

---
Space Kitty Archive · https://space-kitty.com · API: https://space-kitty.com/api/v1 · MCP: https://space-kitty.com/mcp · Premium: $0.20/request via x402 (Base Sepolia (testnet)). Metadata: arXiv (CC0), OpenAlex (CC0), Europe PMC (CC BY/CC0 works), ClinicalTrials.gov.